Using dasatinib (Sprycel), an FDA approved drug for the treatment of chronic myeloid leukemia in adults and acute lymphoblastic anemia in children, Dr. Bennett showed that he could block the interaction between PZR and SHP2 and inhibit PZR tyrosyl phosphorylation in the NSML mice, even at a dose up to 100‐fold lower than that used to treat cancer patients. The gene discussed is PTPN11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.